December 14, 2020 -- Eureka Therapeutics has touted positive preclinical results for its InvisiMask antibody nasal spray.
In a trial in mice, the spray offered protection against SARS-CoV-2 pseudotyped virus for up to 10 hours, according to Eureka Therapeutics. Results were published on the preprint server bioRxiv.
InvisiMask provides an intranasal application of a proprietary antibody thought to be prophylactic against COVID-19. It is designed to neutralize the novel coronavirus in airborne droplets and particles that enter the nasal cavity.
The antibodies were engineered with a proprietary adhesion technology developed to increase retention on respiratory mucosal surfaces, Eureka noted. The spray can also be both stored and used at room temperature.
Eureka is currently preparing to file an investigational new drug application with the U.S. Food and Drug Administration in order to conduct a clinical trial of the nasal spray.